GPIA Takes Firm Stance Against Required Pediatric Studies For Generics
This article was originally published in The Tan Sheet
Generic drug sponsors bear no responsibility for pediatric studies for multisource drugs, the Generic Pharmaceutical Industry Association told FDA in March 3 comments on implementation of FDAMA pediatric exclusivity provisions and the agency's pediatric rule.
You may also be interested in...
AstraZeneca's Prilosec proton pump inhibitor is anticipated to reach over-the-counter shelves in the second quarter of 2001.
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Perrigo promotes in pricing, planning